Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy
OwnerRaouf Rekikinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to an ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle for use as an ophthalmic neuroprotector in treating an optic neuropathy or congenital optic atrophy.
Claims25
-29. (canceled)
A method for treating an optic neuropathy or congenital optic atrophy with an ophthalmic neuroprotector said method comprising administering to a person in need of such treatment an ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle.
A method to maintain or ameliorate the visual function of a person in need of such treatment, said method comprising administering to the person in need of such treatment an ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle.
An ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicles.
An ophthalmic neuroprotector composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle.
Dependencies are inferred from the claim text.